Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Springworks Therapeutics Inc. operates within the Biotechnology & Pharmaceuticals technology area and currently has 4 pending office actions. These matters are handled by 4 distinct examiners, ensuring that the number of examiners is equal to the count of pending actions. This arrangement prevents any individual examiner from having a dominant influence over the company's immediate prosecution outcomes.
Despite the involvement of 4 distinct examiners, all pending office actions are concentrated within 1 distinct art unit. This focus suggests that the company's current patenting efforts are clustered around a specific technical niche within the broader biotechnology field. SIMMONS, CHRIS E is identified as the busiest examiner, holding 1 pending office action.
The presence of distinct examiners within 1 distinct art unit indicates a high level of scrutiny from multiple perspectives within the same technical group. Practitioners should note that while the art unit is consistent, the 4 pending office actions will be subject to the individual interpretations of the different examiners assigned to the cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.6% | +53.8% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 88.7% | +10.2% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18736140 | COMPOSITIONS AND TREATMENTS WITH NIROGACESTAT | SANCHEZ, JUSTIN CHRISTOPHER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19237417 | IMPROVED MIRDAMETINIB TREATMENT | SIMMONS, CHRIS E | 44d overdue |
| 18694483 | METHODS OF TREATING MULTIPLE MYELOMA | DENT, ALANA HARRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19237417 | IMPROVED MIRDAMETINIB TREATMENT | SIMMONS, CHRIS E | 44d overdue |
| 18841882 | Treatment of cutaneous neurofibromas with Mirdametinib | RAMACHANDRAN, UMAMAHESWARI | — |
| 18736140 | COMPOSITIONS AND TREATMENTS WITH NIROGACESTAT | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18694483 | METHODS OF TREATING MULTIPLE MYELOMA | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19237417 | IMPROVED MIRDAMETINIB TREATMENT | SIMMONS, CHRIS E | 1622 | §102§103§112Other | Non-Final OA | 44d overdue | Pending | Jun 13, 2025 |
| 18841882 | Treatment of cutaneous neurofibromas with Mirdametinib | RAMACHANDRAN, UMAMAHESWARI | — | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18736140 | COMPOSITIONS AND TREATMENTS WITH NIROGACESTAT | SANCHEZ, JUSTIN CHRISTOPHER | — | DP | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18694483 | METHODS OF TREATING MULTIPLE MYELOMA | DENT, ALANA HARRIS | — | §102§103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial